期刊文献+

Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients 被引量:12

Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients
在线阅读 下载PDF
导出
摘要 AIM:To evaluate pretreatment serum carcinoembryonic antigen(CEA) as a predictor of survival for patients with locally advanced gastric cancer receiving perioperative chemotherapy.METHODS:We retrospectively studied a cohort of 228 gastric cancer patients who underwent D2 gastrectomy combined with chemotherapy at the Sun Yat-sen University Cancer Center between January 2005 and December 2009.Among them,168 patients received 6-12 cycles of oxaliplatin-based adjuvant(post-operative) chemotherapy,while 60 received perioperative chemotherapy(2 cycles of FOLFOX6 or XELOX before surgery and 4-10 cycles after surgery).Serum CEA was measured using an enzyme immunoassay.The followup lasted until December 2010.RESULTS:In the group that had elevated serum CEA,the difference in survival time between patients receiving perioperative chemotherapy and those receiving adjuvant chemotherapy had no statistical significance(P > 0.05).However,in the group that had normal serum CEA,patients receiving perioperative chemotherapy had a longer survival time.In multivariate analysis,T staging and lymph node metastatic rate were independent prognostic factors for the patients.Perioperative chemotherapy improved the overall survival of patients who had a normal pretreatment CEA level(P = 0.070).CONCLUSION:Normal pretreatment serum CEA is a predictor of survival for patients receiving perioperative chemotherapy. AIM:To evaluate pretreatment serum carcinoembryonic antigen(CEA) as a predictor of survival for patients with locally advanced gastric cancer receiving perioperative chemotherapy.METHODS:We retrospectively studied a cohort of 228 gastric cancer patients who underwent D2 gastrectomy combined with chemotherapy at the Sun Yat-sen University Cancer Center between January 2005 and December 2009.Among them,168 patients received 6-12 cycles of oxaliplatin-based adjuvant(post-operative) chemotherapy,while 60 received perioperative chemotherapy(2 cycles of FOLFOX6 or XELOX before surgery and 4-10 cycles after surgery).Serum CEA was measured using an enzyme immunoassay.The followup lasted until December 2010.RESULTS:In the group that had elevated serum CEA,the difference in survival time between patients receiving perioperative chemotherapy and those receiving adjuvant chemotherapy had no statistical significance(P 〉 0.05).However,in the group that had normal serum CEA,patients receiving perioperative chemotherapy had a longer survival time.In multivariate analysis,T staging and lymph node metastatic rate were independent prognostic factors for the patients.Perioperative chemotherapy improved the overall survival of patients who had a normal pretreatment CEA level(P = 0.070).CONCLUSION:Normal pretreatment serum CEA is a predictor of survival for patients receiving perioperative chemotherapy.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第29期3910-3916,共7页 世界胃肠病学杂志(英文版)
基金 Supported by Grant from the State Key Program of the National Natural Science Foundation of China,No. 81030043
关键词 Carcinoembryonic antigen Perioperative chemotherapy Prognosis Gastric adenocarcinoma Survival 围手术期 癌胚抗原 化疗 患者 胃癌 显示 肿瘤防治中心 生存时间
  • 相关文献

参考文献5

二级参考文献34

共引文献233

同被引文献62

  • 1赵林,应红艳,管梅,程月鹃,王毓洲,白春梅.老年胃癌的临床特点[J].中国医学科学院学报,2010,32(4):412-416. 被引量:49
  • 2Ying Wu,Zhe-Wei Wei,Yu-Long He,Roderich E Schwarz,David D Smith,Guang-Kai Xia,Chang-Hua Zhang.Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer[J].World Journal of Gastroenterology,2013,19(21):3309-3315. 被引量:14
  • 3Ji-Kun Li,Miao Zheng,Chuan-Wen Miao,Jian-Hai Zhang,Guang-Han Ding,Wen-Shen Wu.Peritoneal lavage cytology and carcinoembryonic antigen determination in predicting peritoneal metastasis and prognosis of gastric cancer[J].World Journal of Gastroenterology,2005,11(46):7374-7377. 被引量:12
  • 4宗文宏,赵蓓蕾,吕镗烽.血清NSE、CA15-3和CEA在肺癌中表达的临床意义[J].东南国防医药,2006,8(1):23-24. 被引量:3
  • 5马兴璇,黄慧艳.肿瘤相关物质群检测在肿瘤诊断中的应用[J].检验医学与临床,2007,4(8):739-740. 被引量:19
  • 6Macdonald J S,Smalley S R,Benedetti J,et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. The New England Journal of Medicine . 2001
  • 7Wasaburo Koizumi,Hiroyuki Narahara,Takuo Hara,Akinori Takagane,Toshikazu Akiya,Masakazu Takagi,Kosei Miyashita,Takashi Nishizaki,Osamu Kobayashi,Wataru Takiyama,Yasushi Toh,Takashi Nagaie,Seiichi Takagi,Yoshitaka Yamamura,Kimihiko Yanaoka,Hiroyuki Orita,Masahiro Takeuchi.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial[J]. Lancet Oncology . 2008 (3)
  • 8Asuka Murata,Yoshifumi Baba,Masayuki Watanabe,Hironobu Shigaki,Keisuke Miyake,Ryuichi Karashima,Yu Imamura,Satoshi Ida,Takatsugu Ishimoto,Shiro Iwagami,Yasuo Sakamoto,Yuji Miyamoto,Naoya Yoshida,Hideo Baba.p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma[J].Medical Oncology.2013(4)
  • 9Dae Hoon Kim,Su Mi Kim,Jung Kuk Hyun,Min Gew Choi,Jae Hyung Noh,Tae Sung Sohn,Jae Moon Bae,Sung Kim.Changes in Postoperative Recurrence and Prognostic Risk Factors for Patients with Gastric Cancer who Underwent Curative Gastric Resection during Different Time Periods[J].Annals of Surgical Oncology.2013(7)
  • 10Yung-Jue Bang,Young-Woo Kim,Han-Kwang Yang,Hyun Cheol Chung,Young-Kyu Park,Kyung Hee Lee,Keun-Wook Lee,Yong Ho Kim,Sang-Ik Noh,Jae Yong Cho,Young Jae Mok,Yeul Hong Kim,Jiafu Ji,Ta-Sen Yeh,Peter Button,Florin Sirzén,Sung Hoon Noh.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J].The Lancet.2012(9813)

引证文献12

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部